Extract
The year 2020 has imposed challenges on society and healthcare systems as never encountered for many decades: the word “COVID” will stick in our memories long after it (hopefully) has been controlled. The pandemic has been a tragedy in terms of lives lost, economic damage and the long term consequences to health that are only now being realised. We mourn with our readers the lost colleagues, family members, friends and loved ones. What is the role of a scientific journal in a situation such as this? From early in the pandemic the ERJ has played a key role in the mission of the European Respiratory Society to provide timely information and guidelines to clinicians and an outlet for important scientific research. We hope that the work published in the ERJ in the past year has helped to inform, educate and entertain our readers during the most challenging period of all of our professional lives.
Abstract
The COVID-19 pandemic has led to an unprecedented surge in medical publishing, during which the ERJ has had to weather twice as many manuscript submissions as usual https://bit.ly/38IAidU
Footnotes
Conflict of interest: M. Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape.
Conflict of interest: J.D. Chalmers has received research grants from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Pfizer, Grifols, Bayer AG, Polyphor and Insmed; and received consultancy, congress travel or speaker fees from GlaxoSmithKline, Bayer Healthcare, Aradigm Corporation, Grifols, Pfizer, Boehringer Ingelheim, Napp and Insmed.
Conflict of interest: M. Humbert reports grants and personal fees from Bayer/Merck and GSK, personal fees from Actelion Pharmaceuticals Ltd/Johnson & Johnson, Arena Pharmaceuticals Ltd, Pfizer, United Therapeutics, Astrazeneca, Novartis, Roche/Genentech, Sanofi/Regeneron and Teva; in addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
- Received January 11, 2021.
- Accepted January 13, 2021.
- ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org